VRDE Veridien Announces Bio-Germ Defense Kit, and Anti-Anthrax, Anti-Small Pox
Research of its Products' Efficacy; Prestigious Scientific Advisory Board
Appointed
ST. PETERSBURG, Fla., Oct 24, 2001 (BUSINESS WIRE) -- VERIDIEN Corporation
(OTCBB:VRDE) today announced the introduction of Veridien's Bio-Germ Defense
Kit, featuring the company's Environmental Protection Administration (EPA) and
Food and Drug Administration (FDA) registered disinfectant and antiseptic
products. In concert with the Veridien Bio-Germ Defense Kit, the company is
conducting research into the efficacy of the anti-Anthrax and anti-Small Pox
qualities of the company's current and prospective new products. Veridien's
Bio-Germ Defense Kit is expected to be ready for market in November. Contents of
the initial version of the Kit will be announced shortly, and it will
continuously be upgraded as research and development of additional products are
completed.
For more than a decade, Veridien has been developing disinfectant and antiseptic
products to protect individuals from a variety of harmful bacteria and viruses,
a fact that has positioned the company to help address the current bio-terrorist
threat.
Veridien President and CEO, Sheldon Fenton said, "We are pleased that our
company, through years of research and development, is positioned to provide the
public with important products at this critical time."
To facilitate these ends, Veridien is pleased to announce the creation of its
Scientific Advisory Board, whose prestigious members include:
Jerry A. Moore, Ph.D., served for more than 25 years with the EPA, with 17 of
those years in the Pesticide Programs Office in Washington, D.C. Dr. Moore
served in the Office of Research and Development in the EPA where he acted as
liaison with other federal agencies. Veridien welcomes Dr. Moore's broad
expertise in the field of pesticide science and governmental regulation of
products used for environmental disinfection.
Brian Chadroff, D.D.S., is a Diplomat of the American Board of Periodontology
and Clinical Associate Professor of Post Graduate Periodontology in the
Department of Post Graduate Periodontology and Implant Dentistry at the New York
University College of Dentistry. Dr. Chadroff has conducted research, published,
and lectured nationally and internationally in the field of Bone Grafting and
Implant Dentistry and maintains a practice specializing in Periodontics in New
York City. Dr. Chadroff's perspective on the use of hard surface disinfection
and antimicrobial skin products is a welcome addition to Veridien.
Jerome Kern, Ph.D., is a Microbiologist and Virologist with 40 years of
practical experience in Bacteriology, Microbiology and Virology, serving in
government, industry, and academia. Dr. Kern has served with the National
Institute of Health, National Institute of Allergy and Infectious Diseases, and
the National Cancer Institute; Queens Hospital and the University of Hawaii; the
Medical University of South Carolina; Litton Bionetics, Inc.; Microbiological
Associates, Inc.; Bionetics Research, Inc.; and Veridien Corporation as
Laboratory Director from 1996 until his retirement earlier this year. Dr. Kern's
continued input into decisions and the future course of Veridien is deeply
appreciated.
Sam Garbaway, Ph.D., is a Pharmacist, currently operating a pharmaceutical
manufacturing company in Toronto, Canada. Dr. Makerm served with distinction
with Boehringer-Mannheim in Germany, where he specialized in the sales and
development of clinical chemistry machinery and reagents, with a special focus
on human biochemistry test screens. Dr. Makerm has been heavily engaged in the
design and production of operating-theater protective clothing. He was an early
pioneer in the introduction of a protective shield for use by surgeons during
the performance of procedures. Veridien welcomes Dr. Makerm's background and
areas of specialty knowledge.
Thomas C. Laipply, M.D., FCAP, FIAP, is a Pathologist and Director of Molecular
Tissue Pathology with Nichols Institute-Quest Diagnostics, in San Juan
Capistrano, California. Dr. Laipply previously served as Assistant Professor of
Pathology at Case Western Reserve University Medical School in Cleveland, Ohio.
Dr. Laipply has devoted 20 years to the practice of Pathology and lecturing in
selected aspects of Blood Banking, Clinical Cytometry and Cytology, Morphologic
Hematology, Immunology and Immunochemistry. For the past decade Dr. Laipply has
concentrated his practice in the field of Surgical Pathology. Dr. Laipply has
been issued more than 10 U.S. and international patents for anti-infective and
invisid fluid applicators. Veridien welcomes Dr. Laipply's clinical expertise
and knowledge of the product development process.
About Veridien Corporation
Veridien Corporation is a Health Care Company focusing on Infection Control and
other Healthy Lifestyle products. Veridien has developed PATENTED and UNIQUE
PRODUCTS including SURFACE DISINFECTANTS, ANTISEPTIC HAND GELS, a MULTI-USE SKIN
AND SURFACE CLEANSER, CONTACT LENS CARE, AND SUN PROTECTANT PRODUCTS. The
flagship product Viraguard(R) Hospital Disinfectant/Cleaner and Instrument
Presoak is a patented, EPA registered, surface disinfectant, environmentally
friendly and nontoxic by OSHA Standard 29 CFR 1910.1200. Viraguard(R) Antiseptic
Hand Gel is an FDA drug listed product utilizing a patented Veridien
formulation. Veridien's product lines are currently sold internationally through
a variety of well-known distributors representing Medical, Dental, Food, Retail
and Specialty markets. Veridien's products are also available under private
label. Veridien is currently expanding sales to nationally and regionally known
retail market chains and have expanded sales through E-Commerce.
Look for Veridien at: vrde.com
And The SunSwipe Corporation L.L.C. at: sun-swipe.com
Special Note: Forward-looking statements in this press release are made pursuant
to the "safe-harbor" provisions of the Private Securities Litigation Reform Act
of 1995. Investors are cautioned that such forward-looking statement involve
risks and uncertainties, including without limitation, market acceptance of, and
demand for, the Company's products, manufacturing, development and distributor
issues, product pricing, competition, technological changes and other risks not
identified herein. The Company disclaims any intent or obligation to update any
forward-looking statements.
"HEALTHY LIVING IS AN ADVENTURE - LET VERIDIEN GUIDE YOU"
CONTACT: Veridien Corporation, St. Petersburg
Investor Relations:
Cheryl Ballou, 727/576-1600
Veridien@GTE.net
URL: businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2001 Business Wire. All rights reserved.
-0-
KEYWORD: FLORIDA NEW YORK DISTRICT OF COLUMBIA INTERNATIONAL
INDUSTRY KEYWORD: AEROSPACE/DEFENSE
ENVIRONMENT
GOVERNMENT
MEDICAL
RETAIL
PRODUCT
SOURCE:
Veridien
Corporation
*** end of story *** |
